These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
541 results:

  • 1. Epidermal Growth Factor Receptor Targeting in colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.
    Tardito S; Matis S; Zocchi MR; Benelli R; Poggi A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000238
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants.
    Chen S; Gu J; Wu K; Zhao X; Lu Y
    Cancer Biol Med; 2024 Jun; 21(6):473-83. PubMed ID: 38940668
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Temporal dynamics of RAS mutations in circulating tumor DNA in metastatic colorectal cancer: clinical significance of mutation loss during treatment.
    Iguchi K; Shiozawa M; Uchiyama M; Asari M; Numata K; Rino Y; Saito A
    J Cancer Res Clin Oncol; 2024 May; 150(5):281. PubMed ID: 38805050
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression.
    Zhang X; Zhou W; Wu C; Jiang J; Guo Q; Feng L; Cheng X; Zhang X
    Sci Rep; 2024 May; 14(1):10642. PubMed ID: 38724565
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration.
    Geng Y; Zheng X; Zhang D; Wei S; Feng J; Wang W; Zhang L; Wu C; Hu W
    Biol Direct; 2024 May; 19(1):36. PubMed ID: 38715141
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Predictors for temporary stomas non-closure among non-metastatic rectal cancer patients undergoing curative resection: a retrospective analysis.
    Hsu CC; Tsai WS; Tsai TY; You JF; Yeh CY; Hsieh PS; Tang R; Huang SH
    World J Surg Oncol; 2024 May; 22(1):124. PubMed ID: 38715036
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells.
    Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Göndör A; Östling P; Holmgren L
    J Exp Clin Cancer Res; 2024 Apr; 43(1):107. PubMed ID: 38594748
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with egfr and YBX-1.
    Zhou X; Zhang K; Wang C; Teng Y; Yu P; Cai W; Gao W; Li M; Ding Y; Sun P; Chen F; Wang Y; Ma J; Maeshige N; Ma X; Li Q; Liang X; Zhang Y; Su D
    Cancer Lett; 2024 May; 590():216868. PubMed ID: 38593920
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Indoxyl sulfate contributes to colorectal cancer cell proliferation and increased egfr expression by activating AhR and Akt.
    Ichisaka Y; Yano S; Nishimura K; Niwa T; Shimizu H
    Biomed Res; 2024; 45(2):57-66. PubMed ID: 38556263
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Identification of unique rectal cancer-specific subtypes.
    Kisakol B; Matveeva A; Salvucci M; Kel A; McDonough E; Ginty F; Longley DB; Prehn JHM
    Br J Cancer; 2024 May; 130(11):1809-1818. PubMed ID: 38532103
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
    Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
    Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.
    Patell K; Mears VL; Storandt MH; Mahipal A
    Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):197-205. PubMed ID: 38497279
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [History and Perspective of Chemotherapy in Advanced Esophageal cancer].
    Shiraishi K; Kato K
    Gan To Kagaku Ryoho; 2024 Mar; 51(3):240-244. PubMed ID: 38494800
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Integrative multi-omics characterization reveals sex differences in glioblastoma.
    Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
    Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. BCL-X
    Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
    Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Update on Targeted Therapy and Immunotherapy for Metastatic colorectal cancer.
    Underwood PW; Ruff SM; Pawlik TM
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334637
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The role of anti-egfr rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review.
    Ciardiello D; Mauri G; Sartore-Bianchi A; Siena S; Zampino MG; Fazio N; Cervantes A
    Cancer Treat Rev; 2024 Mar; 124():102683. PubMed ID: 38237253
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A partial epithelial-mesenchymal transition signature for highly aggressive colorectal cancer cells that survive under nutrient restriction.
    Pastorino GA; Sheraj I; Huebner K; Ferrero G; Kunze P; Hartmann A; Hampel C; Husnugil HH; Maiuthed A; Gebhart F; Schlattmann F; Gulec Taskiran AE; Oral G; Palmisano R; Pardini B; Naccarati A; Erlenbach-Wuensch K; Banerjee S; Schneider-Stock R
    J Pathol; 2024 Mar; 262(3):347-361. PubMed ID: 38235615
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Downregulation of Serum miR-133b and miR-206 Associate with Clinical Outcomes of Progression as Monitoring Biomarkers for Metastasis colorectal cancer Patients.
    Wanram S; Klaewkla N; Pinyosri P
    Microrna; 2024; 13(1):56-62. PubMed ID: 38231064
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer.
    Jones VT; Graves-Deal R; Cao Z; Bogatcheva G; Ramirez MA; Harmych SJ; Higginbotham JN; Sharma V; Damalanka VC; Wahoski CC; Joshi N; Irudayam MJ; Roland JT; Ayers GD; Liu Q; Coffey RJ; Janetka JW; Singh B
    Cell Mol Life Sci; 2024 Jan; 81(1):28. PubMed ID: 38212428
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 28.